Abstract: The present invention relates to a hygiene product or a pharmaceutical composition in the form of a gel or dressing, for topical application to the skin or mucosa including glycerol, at least one poly(meth)acrylate polymer, at least one polyethylene glycol having a molecular weight of less than 1000 g/mol, octanediol and water. The composition or dressing can be used for healing treatment of chronic dermal ulcers, healing and soothing treatment of eczema and psoriatic conditions, healing treatment of anal fissures, treatment of mouth injuries, resorption and healing of labial herpes (cold sore) and treatment of dermatitis. The hygiene product can be a shaving or aftershave product for sensitive or hypersensitive skin, a nasal decongestant product or a product for ear hygiene.

Abstract: A wound care bandage for treating a wound is provided. The bandage includes an SIS layer to be placed on the wound surface and a cover to be placed over the wound. The bandage further includes a structure to provide a vacuum space. A method for promoting wound healing is further provided. The method includes applying the above-mentioned wound care bandage to the wound and creating a vacuum in the vacuum space to draw blood controllably from the wound into the SIS layer.

Abstract: A process for preparing a disinfecting wound dressing for the protection of wounds, such as burn wounds, ulcers and cuts, the process comprising the steps of providing a yarn-based substrate, subjecting a surface of the substrate to a plasma environment, thereby providing non-leaching and biocidal features to the substrate surface by exposing the substrate surface to an antimicrobial active compound reaction.

Abstract: This invention relates to topical compositions for combating ectoparasites and endoparasites in animals, comprising at least one isoxazoline active agent and a pharmaceutically acceptable carrier, optionally in combination with one or more additional active agents. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the compositions of the invention to the animal in need thereof.

Abstract: The present disclosure provides amine-modified polymer foams, which may be used for wound dressing materials. For example, the modified materials can include a covalently attached molecule comprising free amine groups. Such amine groups can be used, for instance, to conjugate biologically active polypeptides and/or linkers. Methods for using modified polymers are also provided.

Abstract: An absorbent wound dressing comprises a hydrophilic porous substrate and polymer-stabilized silver nanoparticles distributed throughout the porous substrate. The silver nanoparticles have a particle size d50 in the range of about 45 nm to about 85 nm and the silver nanoparticles are present in the substrate in an amount of about 0.16% to about 1.5% by weight of the total weight of the substrate. The wound dressing produces a 7-day log reduction of 4 or more for bacteria in accordance with the Modified AATCC Test Method 100. The wound dressing is also non-cytotoxic in accordance with ISO 10993-5 standard procedure for medical device cytotoxicity assessment.

Abstract: The present invention relates to gel compositions comprising at least one entrapped active component.

Abstract: A wound barrier pad is provided having a housing with a housing opening. The housing has a truncated conical shape. A base plate with an opening is disposed in the housing, and the housing is filled with a fluid or padding. The wound barrier pad may also be embodied to have a cylindrical shape, a rectangular shape or other shape. The wound barrier pad may be incorporated into a garment. In another embodiment the wound barrier pad includes a ring and an adhesive such that the wound barrier pad may be directly adhered to the patient, thus eliminating the need for the garment. In another embodiment there is a wound barrier device having a pad assembly and an anti-sheer member. The anti-shear member reduces frictional forces on the skin of a patient. In another embodiment a wound barrier assembly is provided for applying a negative pressure to a wound.

Abstract: Methods for incorporating chlorhexidine salts into solvent based adhesives are described. The methods involve freeze drying an aqueous solution of the chlorhexidine salt and obtaining the chlorhexidine salt in a particulate form. The dry powder can then be dissolved into an appropriate solvent used with the adhesive of interest. Also described are particles including chlorhexidine salts that are incorporated in adhesives. Also described are various medical products utilizing the adhesive and chlorhexidine compound, and related methods of use.

Abstract: A pain sensory nerve stimulation apparatus includes: a stimulation electrode which is adapted to be attached to a living body, at least one of an exogenous algesic substance and pyrogen which is to be interposed between the living body and the stimulation electrode; and a stimulation power supplier which is configured to supply electric power to the stimulation electrode.

Abstract: The present description discloses a novel biologically active ingredient of manuka honey. Specially, the present description discloses a compound represented by the following formula. In this formula, each of R1, R2 and R3 independently represents a hydrogen atom or optionally substituted C1-4 alkyl group, m represents an integer from 1 to 3, each of R4-m, R5-m and R6-m independently represents a hydrogen atom or optionally substituted C1-4 alkyl group, and each of R7, R8, R9 and R10 independently represents a hydrogen atom or optionally substituted C1-4 alkyl group.

Abstract: A hemostatic device, method of making, and method of using for internal and external applications to wounds in the body of a patient to induce hemostasis at an anatomical site.

Abstract: One embodiment of the invention is directed to a method of preventing, reducing, or eliminating at least one negative effect of oxidative damage, such as an oral disease, caused by a dental device in the mouth of a patient. Another embodiment relates to a method of preventing, reducing, or eliminating at least one negative effect of inflammation. The method may include applying topically to a soft oral tissue in the patient an oral antioxidant composition. The antioxidant composition may include between 0.0001% and 5.0% w/w or at least one antioxidant, wherein the at least one antioxidant includes a natural phytochemcial antioxidant, a flavonoid, an anthocyanidin, a dihydrochalcone, a phenylpropanoid, a chalcone, a curcuminoid, a tannin, a stilbenoid, a coumarin, a carotenoid, or a vitamin, and an orally pharmaceutically acceptable carrier. The pH of the oral antioxidant composition may be at least 5.0.

Abstract: A wound care bandage for treating a wound is provided. The bandage includes an SIS layer to be placed on the wound surface and a cover to placed over the wound. The bandage further includes a structure to provide a vacuum space. A method for promoting wound healing is further provided. The method includes applying the above-mentioned wound care bandage to the wound and creating a vacuum in the vacuum space to draw blood controllably from the wound into the SIS layer.

Abstract: The present invention provides to a patch and a patch preparation having low stretchability, which can be continuously adhered to the skin for a long time without undesirable detachment and marked falling off from the skin due to various factors during adhesion, and specifically provides a low stretchable patch and a patch preparation containing a support and an adhesive layer formed on one surface of the support, wherein a ratio P of the total length W (mm) of curved sections of a planar outer shape of the patch to the total length S (mm) of straight-line sections of the planar outer shape of the patch (W/S) is not more than 1.22, and, when the curved sections are approximated by a circular arc, the radius R (mm) of the circular arc is not less than 0.5 mm.

Abstract: Improved hemostatic agents take the form of granules or particles that can be used to stanch, seal, or stabilize a site of hemorrhage, including a noncompressible hemorrhage.

Abstract: A bandage includes a reservoir filled with a perfluorochemical fluid, saturated with oxygen. Oxygen passes through a permeable membrane to the skin or wound to promote healing, and carbon dioxide travels from the skin or wound to the reservoir.

Abstract: An improved skin substitute is presented comprised of a silicone layer backed up with a woven nylon fabric layer, the silicone layer possessing a regular pattern of slits that permit the porosity of the skin substitute to be adjusted by clinicians by means of applying tension to the skin substitute that differentially opens the slits. A variety of therapeutic substances can be applied to the skin substitute to promote healing, including aloe and other medicinal preparations.

Abstract: The invention generally relates to dextran fibers which are preferably electrospun and devices formed from such fibers. In particular, such devices may include substances of interest (such as therapeutic substances) associated with the electrospun fibers. Upon exposure to a liquid the electrospun fibers dissolve immediately and the substances of interest are released into the liquid. Exemplary devices include bandages formed from electrospun dextran fibers and associated agents that promote hemostasis, such as thrombin and fibrinogen.

Abstract: The present invention provides hemostatic compositions comprising components of the flowers of pharmaceutical chamomile (Chamomilla recutita) and the leaves of dioecious nettle (Urtica dioica). Further inclusion of a biocompatible polymeric base, particularly an alignate, generates a composition with excellent and broad spectrum hemostatic capabilities, with concurrent antiseptic and anti-inflammatory properties. The invention further provides methods of using the inventive compositions in to reduce or stop bleeding, as well as a variety of apparatuses useful in hemostatic contexts that incorporate the inventive compositions. In one particular embodiment, the invention provides hemostatic dressings in which a polymeric layer incorporating chamomile and nettle components is applied to a textile or fabric material, for example a non-woven viscose.

Abstract: The invention provides compositions, methods and kits for the removal of harmful or irritating substances from bodily surfaces. Kits may include a composition containing capsaicin and a capsaicin-cleansing composition, e.g., a composition in which capsaicin is soluble.

Abstract: The present invention provides a water resistant patch preparation having a central part and a peripheral part, which preparation is comprised of a support and an adhesive layer comprising a drug, which is formed on one surface of the support, wherein at least a part of a lateral end of the adhesive layer in the peripheral part is located inside a lateral end of the support, and the adhesive layer in the peripheral part has a thickness smaller than that of the adhesive layer in the central part.

Abstract: Methods of treating disorders mediated by ?-catenin comprising administration of Nefopam compounds are provided In particular, the treatment of disorders arising from excessive or undesired expression of ?-catenin is contemplated Said compounds include Nefopam, analogues thereof, prodaigs thereof, and salts and solvates of Nefopam The ?-catenin mediated disorders are preferably selected from the group consisting of fibroproliferative disorders (such as scars, aggressive fibramtoses, and fibroses) and cancer (such as colon cancer, melanoma, liver cancer, ovarian cancer, endometrial cancer, medullobalstoma pilomatricomas, and prostate cancer)

Abstract: The present invention relates to the use of p38 MAP kinase inhibitors and p38 MAP kinase inhibition to promote wound healing.

Abstract: An in situ film-forming methyl acetate-based solution of at least one absorbable, segmented block copolymer with amorphous and semi-crystalline segments contains at least one bioactive agent which exhibits antimicrobial, anti-inflammatory, antiviral, anesthetic, hemostatic, and/or antineoplastic activity. The absorbable polymers can be a polyaxial copolyester, polyether-ester and polyether-ester urethane. The solution can be applied (e.g., sprayed or swabbed) onto animal and human skin or accessible body cavities to prevent or treat one or more disorders preventable or treatable by the bioactive agent therein.

Abstract: A wound dressing and a method of making the wound dressing is described herein. The wound dressing is formed of an absorbent substrate formed of one or more layers and a low-adherence layer disposed on the substrate. The low-adherence layer can be disposed within at least a portion of the substrate. The low-adherence layer is formed of a mixture of at least one highly fluorinated polymer and at least one acidic polymer. The at least one highly fluorinated polymer has a fluorine content greater than the fluorine content of the at least one acidic polymer.

Abstract: The present invention includes compositions and methods for the integration of a non-allergenic nanocellulose into a wound bed. The composition may be formed into a wide variety of implants, e.g., a suture, a sheet, a compress, a bandage, a band, a prosthesis, a fiber, a woven fiber, a bead, a strip, a clasp, a prosthesis, a catheter, a screw, a bone plate, a pin, a bandage or combinations thereof.

Abstract: The invention relates to a method for reducing the concentration of amines and salts thereof, wherein the amines have the general chemical formula I R1R2R3N and the salts have the formula II R1R2R3N—H, wherein the amines and salts thereof exist in aqueous solution or aqueous suspension and are brought into contact with clinoptilolitic or clinoptilolite-containing mixtures. The method itself is suitable for use in food preparation and in the manufacture of foods. The inventive idea of reducing the concentration of amines and salts thereof is also useful in the manufacture of medical products for absorbing and for removing amines from the intestinal tract or the skin area of humans and animals.

Abstract: The present invention provides a topical composition comprising (i) an amount of an AP-1 signaling inhibitor sufficient to reduce, delay or prevent apoptosis and/or necrosis induced by dermal wounding and/or to induce and/or enhance proliferation of a cell; and (ii) a suitable carrier or excipient e.g., a topical carrier or excipient or other carrier or excipient for dermal application. For example, the AP-1 signaling inhibitor is a peptide analog comprising the sequence set forth in SEQ ID NO: 104. The present invention also provides a method of treating a dermal wound comprising topically administering said topical composition to a subject suffering from a dermal wound.

Abstract: The present application is drawn to a synthetic, polymer hydrogel-based material, which is able to actively induce the body's natural hemostatic coagulation process in blood or acellular plasma. The present invention provides the development of a primary amine containing polymer hydrogel capable of inducing blood coagulation and delivering therapeutics for hemostatic or wound care applications, and a method of forming such a primary amine containing polymer hydrogel capable of inducing the blood coagulation process. The primary amine containing polymer hydrogel is able to achieve the same end result as biological-based hemostatics, without the innate risk of disease transmission or immunological response, and at a fraction of the price. Furthermore, due to its inherent hydrogel-based design the material has the capability of arresting blood loss while simultaneously delivering therapeutics in a controlled manner, potentially revolutionizing the way in which wounds are treated.

Abstract: The present invention provides a composition, and a method of use thereof, for treating connective tissue damage in man and in animals, which comprises a therapeutically effective amount of chondroitin sulfate, N-acetyl D-glucosamine, and hyaluronan (hyaluronic acid). Particularly, the present invention provides a composition, and a method of use thereof, for treating connective tissue damage including, but not limited to, arthritic disease, osteoarthritis, rheumatoid arthritis, osterochondrosis dessicans, cartilage damage, joint injury, joint inflammation, joint synovitis, degenerative joint disease (DJD), post surgical DJD, traumatic injury, fracture, tendon damage, ligament damage, skeletal damage, musculoskeletal damage, fiber damage, adipose tissue damage, small intestine tissue damage, blood cell damage, and plasma damage. Compositions for delivery of the present invention include those for parenteral, oral, and transmucosal delivery and for direct surgical placement onto the affected tissues.

Abstract: The present invention relates to methods and compositions for rendering a surface resistant to bio-film formation by a combination of an alkanediol and an antimicrobial agent (and, optionally, an organic hydroxy acid). The invention provides for compositions which may be used to render surfaces bio-film resistant, articles having bio-film resistant surfaces, and methods for their preparation. The present invention may be advantageously applied to medical articles as well as articles used in non-medical contexts, such as child care or food preparation.

Abstract: The present invention provides a wound dressing comprising a tessellated water-soluble molding matrix comprised of a polymer selected from the group consisting of polyvinyl alcohol, gelatin, and mixtures thereof and a 1,1-disubstituted ethylene monomer. The present invention further provides methods of using the wound dressing and kits containing the wound dressing.

Abstract: A method of inducing hemostasis in a wound using a hemostatic product. A dextran support is provided. At least one hemostatic agent stabilizer is mixed with at least one hemostatic agent to form a hemostatic agent and stabilizer mixture. The at least one hemostatic agent includes at least one of thrombin and fibrinogen. The hemostatic agent and stabilizer mixture is associated with the dextran support. The hemostatic product is applied to the wound in which a bodily fluid is present. The at least one hemostatic agent is released from the hemostatic product to induce hemostasis in the wound.

Abstract: Reinforced, laminated, impregnated, and materials with composite properties as cross linked polyvinyl alcohol hydrogel structures in bulk or cellular matrix forms that can take essentially any physical shape, or can have essentially any size, degree of porosity and surface texture. They have a wide range of physical properties, unusual and unique combinations of physical properties and unique responses to stress fields, which allows for their use in many end use applications.

Abstract: A peelable pouch comprises a substantially flat enclosure formed by first and second opposing flexible plies. A seat extends along at least a portion of a perimeter of the opposing plies. A flat, flexible transdermal patch is disposed in the enclosure and includes a bioactive agent dissolved in a layer of adhesive. A release liner is removably attached over the layer of adhesive, with the patch and the release liner together being sufficiently resilient so as to generate a spring force when displaced out of the flat configuration. The first and the second plies each being separable along the seal and displaceable out of the flat configuration. The spring force generated by the patch and the release liner being sufficient to overcome an adhesive force created by the adhesive between the patch and one of the plies.

Abstract: Devices and methods relate to inducing or promoting hemostasis. The hemostasis device may include a support layer having a first surface and an opposing second surface. The device may include a layer, the layer disposed on the first surface. The layer may include a target surface configured to contact a target site. The layer may include a monolayer of about 100% graphene or may include laser-reduced graphene oxide. The device may include a sensor configured to measure a level of hemostasis of the target site. The methods relate to a method of manufacturing a hemostatic device including a monolayer of graphene or a layer of laser-reduced graphene oxide.

Abstract: Glycerophosphate salts have been found to hasten the healing of wounds and minimize the formation of scars, particularly when it is first applied to a wound about 0 to about 7 days after the wound is inflicted. Methods and compositions are provided for treating wounds using a composition comprising an effective amount of glycerophosphate salt. In particular, methods are provided for treating wounds using calcium glycerophosphate (CGP), for accelerating the healing process, reducing pain and scar formation, and for the cosmetic reducing, excision, erasure and/or complete repair of scars (scar revision).

Abstract: A composite comprising a stem cell; a biodegradable layer, which can provide an environment for the stem cell to grow and to differentiate, and; a N-isopropylacrylamide (NIPAAm), which can polymerize with the biodegradable layer and possess the temperature-responsive character for easy stripping. The present invention further provides a method for treating a patient with a skin defect, consisting of (a) providing said patient with a composite consisting of a N-isopropylacrylamide (NIPAAm) layer polymerized with a biodegradable layer containing gelatin and a layer of polypropylene (PP) non-woven, wherein a bone marrow derived mononuclear cell with CD45 negative and glycophorin A negative is cultivating on the biodegradable layer; (b) covering said composite on the skin defect of the patient; and (c) treating the composite with water below 25° C. to strip off the layer of polypropylene (PP) non-woven.

Abstract: This invention provides the use of one or more peptides derived from the C-terminal end of a Chemerin protein, or analogs, or derivatives thereof for treatment of inflammation and/or endotoxic shock and/or treatment of wounds and/or reduction of levels of inflammatory chemokines in a subject, and one or more peptides derived from the C-terminal end of a Chemerin protein, or analogs or derivatives thereof for use in the treatment of inflammation and/or endotoxic shock, and/or wounds, or for the reduction or levels of inflammatory mediators.

Abstract: Cationic peptides and use of such peptides to inhibit bacterial exotoxin production without substantially inhibiting bacterial growth are described.

Abstract: A digital measurement system and method for optical applications including a mobile client device having a digital camera and an audio port, and a laser measurement device having a laser and a magnetic card reader. The laser measurement device and the magnetic card reader are electrically connected to the audio port of the mobile client device. The mobile client device is configured to activate the laser at the same time as the digital camera is activated, capture an image of a patient, and calculate position of wear measurements based on a location of a laser mark in the captured image. The mobile client device also allows an order for a frame and lenses to be submitted to a ophthalmic laboratory, and payment transactions to be processed using the magnetic card reader.

Abstract: The present disclosure provides antimicrobial compounds, compositions comprising such antimicrobial compounds, and methods of their use, in particular, antibacterial compounds and antifungal compounds. In certain aspects, the antimicrobial compounds are effective against pathogens of hospital-acquired infections. In certain aspects, the antimicrobial compounds are effective against pathogens that are resistant to antibiotics. The antimicrobial compounds can be used in antibacterial compositions, antifungal compositions, antiseptic compositions and disinfectant compositions. The antimicrobial compounds can be used as adjuncts in antibacterial compositions and antifungal compositions.

Abstract: Disclosed are compositions comprising a hydrophilic polymer, a hydrophobic polymer, a silver ion, and a chlorite anion, wherein the silver ion associates with at least one hydrophilic or hydrophobic polymer, and wherein the chlorite ion associates with the hydrophilic polymer. Also disclosed are methods of making a photo-stable silver ion and chlorite ion containing wound dressing and methods of reducing or preventing infection of a wound by using the compositions and wound dressings of the present invention.

Abstract: Provided is a method of activating osteogenic or chondrogenic activity at a site in a subject in need thereof. Also provided is a method of treating a bone or cartilage defect in a subject. Additionally, the use of a reduced pressure apparatus for treating a bone or cartilage defect adjacent to dura mater, periosteum, or endosteum is provided. Further provided is a composition for treating a bone or cartilage defect. Also, the use of a reduced pressure apparatus and a biocompatible scaffold for the manufacture of a composition for treating a bone or cartilage defect adjacent to dura mater, periosteum or endosteum is provided.

Abstract: The invention relates to a topical patch comprising a therapeutic compound-impermeable backing layer, a self-adhesive matrix based on polysiloxanes and containing capsaicin or a therapeutic compound analogous to capsaicin, and a protective film to be removed before use, in which the matrix contains liquid microreservoirs based on an amphiphilic solvent, in which the therapeutic compound is present in completely dissolved form and the concentration of the therapeutic compound in the microreservoir droplets is below the saturation concentration. The invention furthermore relates to a process for its production and its use in the treatment of neuropathic pain.

Abstract: The present invention utilizes a combination of a porous carrier and an adsorbent such as a molecular sieve to make a more effective hemostatic device to treat wounds in mammalian animals. These hemostatic devices contain additives that do not inhibit hemostasis.

Abstract: Described are hemostasis devices useful for implantation in biopsy tracts, which device comprise highly compact, dried hemostatic sponge elements. Preferred devices also include compacted sponge matrices exhibiting high density and rigidity in combination with high volumetric expandability when wetted. Also described are methods for making and using such devices.

Abstract: The present invention provides novel therapeutic antimicrobial peptides that are bactericides and have an inhibitory effect on biofilms produced by biofilm-forming bacteria and especially biofilm-forming staphyloccocal bacteria. The invention includes the nucleic acids encoding the polypeptides, methods of treating bacterial infections, medical devices or implants or prosthetics impregnated with, covered or coated in the polypeptides, and means of delivery of the peptide to the oral cavity.

Abstract: The present invention relates to pH-sensitive mucoadhesive film-forming gels and wax-film composites suitable for topical and mucosal delivery of molecules of interest, namely active pharmaceuticals. The gels comprise a pharmaceutically acceptable pH-sensitive polymer that responds to a lowering of pH by precipitating into films when in contact with the skin or mucosal surface. The films also comprise an adhesive polymer that allows the film to remain in contact with the tissue for an extended period of time. The wax-film composites comprise a bi-layer film having both the said pH-sensitive mucoadhesive layer to promote strong adherence to the skin and mucosal surfaces as well as a specially bonded wax layer intended to extend the adherence of the film to tissues for a prolonged period of time.